•We report a case of malignant cardiac tamponade secondary to ovarian carcinoma•We emphasize the quick and fatal outcome of such a complication•It seems that aggressive treatment offers the longest overall survival.

An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in ...

Despite advances in cytotoxic chemotherapy and surgical cytoreduction, disease recurrence continues to be a troubling problem in patients with advanced-stage epithelial ovarian cancer (EOC). Malignant ascites affects approximately 10% of patients with recurrent EOC and is associated with troublesome symptoms, including abdominal pressure, distension, dyspnea, pelvic pain, and bowel/bladder dysf...

conclusions hpv type 16 was detected in only 9.67% of malignant epithelial tumors. it appears that hpv infection plays a relatively minor role in the pathogenesis of ovarian carcinomas. results out of the eight cases with functional cysts only one case (12.5%) expressed hpv. no hpv expression was seen in cases with benign and borderline tumors. out of the 31 cases with one malignant surface epi...

Epithelial Ovarian Carcinoma (EOC), a type of cancer that is usually diagnosed in advanced stages. To date, standard treatment EOC surgery with neoadjuvant or adjuvant platin and taxane based systemic chemotherapy. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) considered cases recurrence EOC. HIPEC has been accepted as gold standart for the pseudomyoxoma peritonei ovarian app...

The surgical management of advanced epithelial ovarian cancer involves cytoreduction, or removal of grossly-evident tumor. Residual disease after surgical cytoreduction of ovarian cancer has been shown to be strongly associated with survival. The goal of surgery is "optimal" surgical cytoreduction, which is generally defined as residual disease of 1 cm or less. However, the designation of "opti...

The 11-year survival of a woman with recurrent progressive advanced epithelial ovarian cancer emphasizes the potential for the disease process to be quite 'chronic' in nature.